

VERSION WITH MARKINGS SHOW CHANGES MADE:

50 (Twice Amended). A method [for inhibiting the action of TNF for] of treating [muscular diseases in a human] muscular dystrophies, polymyositis-dermatomyositis and muscle injuries in a human by inhibiting the action of TNF [by administering a TNF antagonist for reducing the inflammation of muscle of said human, or for modulating the immune response affecting the muscle of said human,] comprising the step of [: a)] administering a therapeutically effective dosage level to said human of [said] a TNF antagonist selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), [and other agents containing soluble TNF receptors,] CDP571 (a humanized monoclonal anti-TNF-alpha antibody), [other monoclonal anti-TNF-alpha antibodies, TNF - alpha converting enzyme inhibitors] and D2E7 (a human anti-TNF mAb) for reducing the inflammation of muscle of said human, or for modulating the immune response affecting the muscle of said human.